CD4 and neoplasm: As MHC-II is expressed by tumor cells in a large proportion of patients, and given the fact that when properly activated, CD4+ T-cells can kill MHC-II positive PDAC cells, we reasoned that MHC-II molecules on PDAC cells could be harnessed for neo-antigen-based immunotherapy.